12,372 trials
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Nasal Cavity
Primary: Overall Survival: Time From Randomization to Death From Any Cause — 74.9; 72.8 percentage of participants — p=0.68
Pulmonary Disease, Chronic Obstructive
Primary: Rate of Moderate or Severe Exacerbations in Participants in the High Stratum — 1.71; 1.40 Moderate/severe exacerbations per year — p==0.036
Open-angle Glaucoma · Ocular Hypertension
Primary: IOP (Intraocular Pressure) — 23.93; 23.89; 22.67; 22.77 mmHg
Severe Hemophilia A
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) as Measured by One-stage Activated Partial Thromboplastin Time (aPTT) Clotting Assay for…
Arthritis, Rheumatoid
Primary: Modified Total Sharp Score (mTSS) at Month 6 — 20.50; 18.85; 17.54 score on a scale
Ocular Hypertension · Open-angle Glaucoma
Primary: Intraocular Pressure (IOP) — 23.51; 23.45; 23.50; 22.31 mmHg
Pulmonary Disease, Chronic Obstructive
Primary: Rate of Moderate or Severe Exacerbations — 1.49; 1.19; 1.27 Moderate/severe exacerbations per year — p=0.068
Infertility · Ovulation Induction · In-Vitro Fertilization
Primary: Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP) — 159 subjects
Seasonal Allergic Rhinitis (SAR)
Primary: Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score (rTNSS) — 10.3; 10.1; 10.2; 10.2 units on a scale — p=<0.001
Ocular Hypertension · Glaucoma
Primary: Extent of Exposure — 224.4; 101.8; 314.6 days
Multiple Sclerosis
Primary: Change From Baseline in Timed Up and Go (TUG) Test Time at 6 Weeks — -0.7; -1.3 change in seconds from basline
Hemorrhagic Fever, Ebola
Primary: Laboratory-confirmed Ebola (Study Diagnostics) — 0; 0 Participants
Acute Pain
Primary: Patient Reported Change in Pain Intensity From Initial Administration of Analgesics (Baseline) to 60 Minutes Post-baseline. — 5.5; 4.5 units on a scale
Chronic Hepatitis C · HCV · Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98 percentage of participants
Acute Myeloid Leukemia
Primary: Day 22 Minimal Residual Disease (MRD) Measured by Flow Cytometry — 42; 57; 79; 64 Participants — p=0.035